DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

Phase 3

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: Levodopa-Carbidopa Intestinal Gel
Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)
Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets

First Posted Date: 2012-11-29

Last Posted Date: 2021-07-16

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 39

Registration Number: NCT01736176

A Study to Evaluate Chronic Hepatitis C Infection

Phase 3

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ABT-450/r/ABT-267, ABT-333
Drug: Ribavirin
Drug: Placebo for ABT-450/r/ABT-267
Drug: Placebo for ABT-333
Drug: Placebo for ribavirin

First Posted Date: 2012-10-30

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 636

Registration Number: NCT01716585

Clinical Practice of Inhalation Anesthesia With Sevoflurane in China

Completed

Conditions: Anesthesia, General

First Posted Date: 2012-10-29

Last Posted Date: 2014-08-19

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 4100

Registration Number: NCT01715857

Locations: 🇨🇳
Site Reference ID/Investigator# 84316, Beijing, Xicheng District, China
🇨🇳
Site Reference ID/Investigator# 86755, Beijing, China
🇨🇳
Site Reference ID/Investigator# 96155, Beijing, China

and more 33 locations

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Phase 3

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ABT-450/r/ABT-267, ABT-333
Drug: Ribavirin
Drug: Placebo for ABT-450/r/ABT-267
Drug: Placebo for ABT-333
Drug: Placebo for ribavirin

First Posted Date: 2012-10-29

Last Posted Date: 2021-08-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 395

Registration Number: NCT01715415

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Adalimumab, current formulation
Biological: Adalimumab, new formulation

First Posted Date: 2012-10-23

Last Posted Date: 2014-06-11

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 100

Registration Number: NCT01712178

Locations: 🇺🇸
Site Reference ID/Investigator# 75077, Hemet, California, United States
🇺🇸
Site Reference ID/Investigator# 83133, Philadelphia, Pennsylvania, United States
🇩🇪
Site Reference ID/Investigator# 78014, Ratingen, Germany

and more 18 locations

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

Phase 3

Completed

Conditions: Chronic Hepatitis C Infection
Compensated Cirrhosis

Interventions: Drug: ABT-450/r/ABT-267, ABT-333
Drug: Ribavirin (RBV)

First Posted Date: 2012-10-11

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 381

Registration Number: NCT01704755

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-126

First Posted Date: 2012-09-21

Last Posted Date: 2021-08-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 343

Registration Number: NCT01690195

Locations: 🇺🇸
Site Reference ID/Investigator# 84187, Hamden, Connecticut, United States
🇨🇦
Site Reference ID/Investigator# 84173, Gatineau, Canada
🇿🇦
Site Reference ID/Investigator# 84391, Cape Town, South Africa

and more 36 locations

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Phase 1

Completed

Conditions: Lupus Erythematosus

Interventions: Drug: ABT-199
Other: Placebo

First Posted Date: 2012-09-18

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 97

Registration Number: NCT01686555

Locations: 🇺🇸
Site Reference ID/Investigator# 89694, Clearwater, Florida, United States
🇺🇸
Site Reference ID/Investigator# 124116, Miami Lakes, Florida, United States
🇺🇸
Site Reference ID/Investigator# 78256, Overland Park, Kansas, United States

and more 12 locations

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: ABT-450/r
Drug: ABT-267
Drug: Ribavirin (RBV)

First Posted Date: 2012-09-14

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 316

Registration Number: NCT01685203

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: ABT-199
Drug: Rituximab

First Posted Date: 2012-09-11

Last Posted Date: 2023-06-06

Lead Sponsor: AbbVie

Target Recruit Count: 49

Registration Number: NCT01682616

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine /ID# 71593, Chicago, Illinois, United States
🇺🇸
North Shore University Hospital /ID# 71813, New Hyde Park, New York, United States
🇦🇺
Peter MacCallum Cancer Ctr /ID# 70394, Melbourne, Victoria, Australia

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy